146 related articles for article (PubMed ID: 22301901)
1. Willingness to pay for obesity pharmacotherapy.
Doyle S; Lloyd A; Birt J; Curtis B; Ali S; Godbey K; Sierra-Johnson J; Halford JC
Obesity (Silver Spring); 2012 Oct; 20(10):2019-26. PubMed ID: 22301901
[TBL] [Abstract][Full Text] [Related]
2. Preferences for improvements in attributes associated with basal insulin: a time trade-off and willingness-to-pay survey of a diabetic and non-diabetic population in Sweden.
Olofsson S; Norrlid H; Persson U
J Med Econ; 2016 Oct; 19(10):945-58. PubMed ID: 27149402
[TBL] [Abstract][Full Text] [Related]
3. Weight loss experiences and willingness to intervention with pharmacotherapy among obese and very obese Danish people.
Jain P; Røstbjerg AS; Haase CL; Rhee NA
Phys Sportsmed; 2016 Sep; 44(3):201-7. PubMed ID: 27254773
[TBL] [Abstract][Full Text] [Related]
4. Economic evaluation of weight loss interventions in overweight and obese women.
Roux L; Kuntz KM; Donaldson C; Goldie SJ
Obesity (Silver Spring); 2006 Jun; 14(6):1093-106. PubMed ID: 16861615
[TBL] [Abstract][Full Text] [Related]
5. Willingness to pay for improvements in chronic long-acting insulin therapy in individuals with type 1 or type 2 diabetes mellitus.
Lloyd A; Nafees B; Barnett AH; Heller S; Ploug UJ; Lammert M; Bøgelund M
Clin Ther; 2011 Sep; 33(9):1258-67. PubMed ID: 21862132
[TBL] [Abstract][Full Text] [Related]
6. Influence of body mass index on prescribing costs and potential cost savings of a weight management programme in primary care.
Counterweight Project Team
J Health Serv Res Policy; 2008 Jul; 13(3):158-66. PubMed ID: 18573765
[TBL] [Abstract][Full Text] [Related]
7. Patient Preferences for Bariatric Surgery: Findings From a Survey Using Discrete Choice Experiment Methodology.
Rozier MD; Ghaferi AA; Rose A; Simon NJ; Birkmeyer N; Prosser LA
JAMA Surg; 2019 Jan; 154(1):e184375. PubMed ID: 30484820
[TBL] [Abstract][Full Text] [Related]
8. Patient Preferences for Preventive Migraine Treatments: A Discrete-Choice Experiment.
Mansfield C; Gebben DJ; Sutphin J; Tepper SJ; Schwedt TJ; Sapra S; Shah N
Headache; 2019 May; 59(5):715-726. PubMed ID: 30861110
[TBL] [Abstract][Full Text] [Related]
9. Liraglutide: A New Option for the Treatment of Obesity.
Nuffer WA; Trujillo JM
Pharmacotherapy; 2015 Oct; 35(10):926-34. PubMed ID: 26497479
[TBL] [Abstract][Full Text] [Related]
10. The Challenges and Opportunities Associated with Reimbursement for Obesity Pharmacotherapy in the USA.
Baum C; Andino K; Wittbrodt E; Stewart S; Szymanski K; Turpin R
Pharmacoeconomics; 2015 Jul; 33(7):643-53. PubMed ID: 25686799
[TBL] [Abstract][Full Text] [Related]
11. Willingness to pay for health improvements associated with anti-diabetes treatments for people with type 2 diabetes.
Jendle J; Torffvit O; Ridderstråle M; Lammert M; Ericsson A; Bøgelund M
Curr Med Res Opin; 2010 Apr; 26(4):917-23. PubMed ID: 20163195
[TBL] [Abstract][Full Text] [Related]
12. Type 2 diabetes patients' preferences and willingness to pay for lifestyle programs: a discrete choice experiment.
Veldwijk J; Lambooij MS; van Gils PF; Struijs JN; Smit HA; de Wit GA
BMC Public Health; 2013 Nov; 13():1099. PubMed ID: 24289831
[TBL] [Abstract][Full Text] [Related]
13. Willingness to pay for continued delivery of a lifestyle-based weight loss program: The Hopkins POWER trial.
Jerome GJ; Alavi R; Daumit GL; Wang NY; Durkin N; Yeh HC; Clark JM; Dalcin A; Coughlin JW; Charleston J; Louis TA; Appel LJ
Obesity (Silver Spring); 2015 Feb; 23(2):282-5. PubMed ID: 25557807
[TBL] [Abstract][Full Text] [Related]
14. An update on the pharmacological treatment of obesity.
Schnee DM; Zaiken K; McCloskey WW
Curr Med Res Opin; 2006 Aug; 22(8):1463-74. PubMed ID: 16870072
[TBL] [Abstract][Full Text] [Related]
15. Medications for weight loss.
Mordes JP; Liu C; Xu S
Curr Opin Endocrinol Diabetes Obes; 2015 Apr; 22(2):91-7. PubMed ID: 25692921
[TBL] [Abstract][Full Text] [Related]
16. [Long-term drug therapy of obesity in 2002--pharmacoeconomic aspects].
Minarcíková I
Ceska Slov Farm; 2003 Sep; 52(5):258-61. PubMed ID: 14619705
[TBL] [Abstract][Full Text] [Related]
17. Use of willingness to pay to study values for pharmacotherapies for migraine headache.
Lenert LA
Med Care; 2003 Feb; 41(2):299-308. PubMed ID: 12555057
[TBL] [Abstract][Full Text] [Related]
18. High-risk individuals' willingness to pay for diabetes risk-reduction programs.
Johnson FR; Manjunath R; Mansfield CA; Clayton LJ; Hoerger TJ; Zhang P
Diabetes Care; 2006 Jun; 29(6):1351-6. PubMed ID: 16732020
[TBL] [Abstract][Full Text] [Related]
19. Assessing the value of symptom relief for patients with gastroesophageal reflux disease treatment: willingness to pay using a discrete choice experiment.
Deal K; Marshall D; Dabrowski D; Charter A; Bukoski M; Moayyedi P
Value Health; 2013 Jun; 16(4):588-98. PubMed ID: 23796293
[TBL] [Abstract][Full Text] [Related]
20. To explore preferences and willingness to pay for attributes regarding stoma appliances amongst patients in the UK, France and Germany.
Nafees B; Lloyd A; Elkin E; Porret T
Curr Med Res Opin; 2015 Apr; 31(4):687-95. PubMed ID: 25651482
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
